Skip to main content
      In high-risk psoriasis patients with nail disease, Secukinumab reduced PsA onset over 5 years with a total exposure of 1

      Antoni Chan MD (Prof) synovialjoints

      1 week 5 days ago
      In high-risk psoriasis patients with nail disease, Secukinumab reduced PsA onset over 5 years with a total exposure of 1022 patient-years. Annual incidence dropped from 2.7 to 0.49 per 100 patient-years. Data from the real world SERENA study. Abstract 1463 @RheumNow #ACR25
      In this MTX+PNL vs TCZ+PNL in GCA study, we saw 5 pts on MTX+PNL get PJP, very surprising.

      @EBRheum asked what I knew/h

      David Liew drdavidliew

      1 week 5 days ago
      In this MTX+PNL vs TCZ+PNL in GCA study, we saw 5 pts on MTX+PNL get PJP, very surprising. @EBRheum asked what I knew/hoped he’d ask: why did this happen? PJP is v rare in GCA (https://t.co/oPN0dpvG8Q) & with MTX in other diseases. Worth interrogation! #ACR25 ABST0891 @RheumNow https://t.co/rsbScryIFR
      POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib
      Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD
      MDA 12% vs

      Aurelie Najm AurelieRheumo

      1 week 5 days ago
      POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD MDA 12% vs 22% All elements of MDA response sig different except for Leeds enthesitis index DAPSA Remission 2% vs. 9% PsARC 42% vs. 61% PASDAS -1 vs. -1.7 mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp
      GLP-1 receptor agonists reduce mortality in PsA

      Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA no

      Brian Jaros, MD Dr_Brian_MD

      1 week 5 days ago
      GLP-1 receptor agonists reduce mortality in PsA Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not After propensity matching, those treated with GLP-1: - lower risk MACE - lower risk overall death @RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj
      Is MTX worth anything in GCA?

      METOGiA: MTX 52w vs TCZ 52w for GCA
      MTX didn’t achieve non-inferiority to TCZ, but:
      - c

      David Liew drdavidliew

      1 week 5 days ago
      Is MTX worth anything in GCA? METOGiA: MTX 52w vs TCZ 52w for GCA MTX didn’t achieve non-inferiority to TCZ, but: - clearly it does something - continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC #ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ
      In pooled PsA trials (n=1222), deucravacitinib reduced disease activity–linked proteomic scores in both sexes by Week

      Antoni Chan MD (Prof) synovialjoints

      1 week 5 days ago
      In pooled PsA trials (n=1222), deucravacitinib reduced disease activity–linked proteomic scores in both sexes by Week 16. Proteomic profiling identified 133 unique proteins in males and 177 in females vs sex-matched healthy controls. Females showed greater enrichment in https://t.co/TTAWUtOLP0
      #ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 5 days ago
      #ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH
      Abstract 0874:
      At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures

      Akhil Sood MD, MS AkhilSoodMD

      1 week 5 days ago
      Abstract 0874: At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures 🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses 🔹 Greater ↓in PASDAS and mCPDAI 🔹 Benefits seen in both men and women @RheumNow #ACR25
      Sex based differences in PsA proteomics

      Analyse from POETYK PSA 1 & 2 deucravacitinib RCT

      Large overlap but female

      Aurelie Najm AurelieRheumo

      1 week 5 days ago
      Sex based differences in PsA proteomics Analyse from POETYK PSA 1 & 2 deucravacitinib RCT Large overlap but female pts specificities, Upregulation of: -JAK STAT pathway -Cytokine interaction Linked with higher disease activity in female groups Yes Correlation, but not https://t.co/VwiVOkxpoB
      Open-label MTX vs. Toci in GCA in METOGiA

      Wk 78:
      37% w/o relapse in MTX arm
      46% w/o relapse in Toci arm

      MTX was

      Brian Jaros, MD Dr_Brian_MD

      1 week 5 days ago
      Open-label MTX vs. Toci in GCA in METOGiA Wk 78: 37% w/o relapse in MTX arm 46% w/o relapse in Toci arm MTX was NOT non-inferior to Toci Toci superior in 2ndary endpoints Cumulative doses GC not significantly different #ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C
      List of GLP1 agonists approved currently..would they have effects in #OA
      Session title is should we gave them to everyon

      Bella Mehta bella_mehta

      1 week 5 days ago
      List of GLP1 agonists approved currently..would they have effects in #OA Session title is should we gave them to everyone? #ACR25 @RheumNow https://t.co/dXwB6Jkg8C
      HOPE for Pts w #fibromyalgia #FM

      #Transcutaneous #electrical #nerve #stimulation + #physio
      Is
      Better than #PT alone

      Janet Pope Janetbirdope

      1 week 5 days ago
      HOPE for Pts w #fibromyalgia #FM #Transcutaneous #electrical #nerve #stimulation + #physio Is Better than #PT alone #Pragmatic #cluster #randomized #trial Answered impt question Does #TENS help Pts w #fibro Too ba noTENS sham Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN
      Open label noninferiority RCT "METOGiA" in GCA

      TCZ improved relapse free survival (83% vs 67% MTX) & pred free remi

      Mike Putman EBRheum

      1 week 5 days ago
      Open label noninferiority RCT "METOGiA" in GCA TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78 Everyone also got pred; are we sure MTX works at all? @RheumNow #ACR25 #ACRBest Abstr#0891 https://t.co/i48JBnawB7
      ×